Rosiglitazone and delayed onset of proliferative diabetic retinopathy

Archives of Ophthalmology

Volumn 126, Issue 6, 2008, Pages 793-799

  Shen, Lucy Q ^a,e   Child, Angie ^a   Weber, Griffin M ^a,b   Folkman, Judah ^a,c   Aiello, Lloyd Paul ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ROSIGLITAZONE;

ADULT; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; EYE CARE; FEMALE; FOLLOW UP; HUMAN; LEG EDEMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RANK SUM TEST; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MACULAR EDEMA; MALE; MEDICAL RECORDS; MIDDLE AGED; PPAR GAMMA; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; THIAZOLIDINEDIONES; VISUAL ACUITY;

EID: 45149096016     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.6.793     Document Type: Article

References (49)

1. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21(1):143-156.
2. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445-450.
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
4. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223-232.
5. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report No. 8. Ophthalmology. 1981;88(7):583-600.
6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol. 1985;103(12):1796-1806.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
8. UK Prospective Diabetes Study Group. Tight intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998;352(9131):837-853.
9. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136(1):122-135.
10. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report No. 14. Int Ophthalmol Clin. 1987;27(4):239-253.
11. Pender PM, Benson WE, Compton H, Cox GB. The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology. 1981;88(7):635-638.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
14. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med. 2000;17(4):287-294.
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem. 1995;270(22):12953-12956.
16. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43(3):278-284.
17. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther. 2004;6(6):850-863.
18. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274(13):9116-9121.
19. Murata T, Hata Y, Ishibashi T, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001;119(5):709-717.
20. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(8):2309-2317.
21. Panigrahy D, Singer S, Shen LQ, et al. PPAR-γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110(7):923-932.
22. Freed MI, Allen A, Jorkasky DK, DiCicco RA. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol. 1999;55(1):53-56.
23. Bursell SE, Cavallerano JD, Cavallerano AA, et al. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology. 2001;108(3):572-585.
24. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123(9):1273-1275.
25. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006;26(5):562-570.
26. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226-1232.
27. Kim KY, Cheon HG. Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor γ-activated maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem. 2006;281(19):13503-13512.
28. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR-γ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis. 2005;8(4):373-379.
29. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS Report No. 12. Ophthalmology. 1991;98(5)(suppl):823-833.
30. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care. 2003;26(12):3273-3279.
31. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;132(5):760-776.
32. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006.
33. Haupt E, Benecke A, Haupt A, Herrmann R, Vogel H, Walter C. The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still performing a profession: prevalence and correlation with duration of diabetic state, BMI and C-peptide. Exp Clin Endocrinol Diabetes. 1999;107(7):435-441.
34. Manaviat MR, Afkhami M, Shoja MR. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol. 2004;4:9. http://www. biomedcentral.com/1471-2415/4/9. Accessed September 1, 2007.
35. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes. 2005;54(7):2206-2211.
36. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005;70(1):20-25.
37. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med. 1995;12(6):482-487.
38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713-720.
39. Sotiropoulos KB, Clermont A, Yasuda Y, et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain. FASEB J. 2006;20(8):1203-1205.
40. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815-821.
41. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 2003;115(suppl 8A):111S-115S.
42. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust. 2002;176(8):381-386.
43. Center for Drug Evaluation and Research, US Food and Drug Administration. Drug approval package for Avandia (rosiglitazone maleate) tablets. http://www.fda.gov/cder/foi/nda/99/21071_avandia.htm. Accessed May 2007.
44. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003;26(6):1852-1855.
45. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
46. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356(24):2522-2524.
47. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007;357(1):28-38.
48. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105.
49. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112(18):2792-2798.